Cargando…
Immunological Studies in Acute Myeloid Leukaemia: PHA Responsiveness and Serum Inhibitory Factors
Sera from 16 of 20 patients with AML at some stage of the disease inhibited the in vitro PHA transformation of normal lymphocytes assessed by measuring the rate of DNA synthesis after 67-70 hours; 42% of pretreatment sera were inhibitory. Inhibitory activity was overcome at PHA concentrations 2-3 ti...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1973
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2008775/ https://www.ncbi.nlm.nih.gov/pubmed/4511988 |
_version_ | 1782135984232595456 |
---|---|
author | Walker, J. S. Davis, D. Davies, P. Freeman, C. B. Harris, R. |
author_facet | Walker, J. S. Davis, D. Davies, P. Freeman, C. B. Harris, R. |
author_sort | Walker, J. S. |
collection | PubMed |
description | Sera from 16 of 20 patients with AML at some stage of the disease inhibited the in vitro PHA transformation of normal lymphocytes assessed by measuring the rate of DNA synthesis after 67-70 hours; 42% of pretreatment sera were inhibitory. Inhibitory activity was overcome at PHA concentrations 2-3 times greater than the concentration which allowed maximum discrimination between NHS and leukaemia sera. PHA transformation of washed lymphocytes obtained from AML patients before treatment and when receiving induction or consolidation (cytoreductive) chemotherapy was reduced only when cultures contained a high proportion of primitive cells. Even in primitive cell contaminated cultures significant responses to PHA could be measured if conditions were modified to prevent increasing acidity. Reports of reduced in vitro immunological reactions in pretreatment and poor prognosis patients may therefore be due to the presence of primitive cells in culture, and in treated patients to the failure of chemotherapy to reduce the circulating primitive cell count. Serum inhibitory factors may have a significant immunosuppressive effect in vivo, but the accurate assessment of the role of immune mechanisms in AML should attempt the measurement of specific immunity. |
format | Text |
id | pubmed-2008775 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1973 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-20087752009-09-10 Immunological Studies in Acute Myeloid Leukaemia: PHA Responsiveness and Serum Inhibitory Factors Walker, J. S. Davis, D. Davies, P. Freeman, C. B. Harris, R. Br J Cancer Articles Sera from 16 of 20 patients with AML at some stage of the disease inhibited the in vitro PHA transformation of normal lymphocytes assessed by measuring the rate of DNA synthesis after 67-70 hours; 42% of pretreatment sera were inhibitory. Inhibitory activity was overcome at PHA concentrations 2-3 times greater than the concentration which allowed maximum discrimination between NHS and leukaemia sera. PHA transformation of washed lymphocytes obtained from AML patients before treatment and when receiving induction or consolidation (cytoreductive) chemotherapy was reduced only when cultures contained a high proportion of primitive cells. Even in primitive cell contaminated cultures significant responses to PHA could be measured if conditions were modified to prevent increasing acidity. Reports of reduced in vitro immunological reactions in pretreatment and poor prognosis patients may therefore be due to the presence of primitive cells in culture, and in treated patients to the failure of chemotherapy to reduce the circulating primitive cell count. Serum inhibitory factors may have a significant immunosuppressive effect in vivo, but the accurate assessment of the role of immune mechanisms in AML should attempt the measurement of specific immunity. Nature Publishing Group 1973-03 /pmc/articles/PMC2008775/ /pubmed/4511988 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Articles Walker, J. S. Davis, D. Davies, P. Freeman, C. B. Harris, R. Immunological Studies in Acute Myeloid Leukaemia: PHA Responsiveness and Serum Inhibitory Factors |
title | Immunological Studies in Acute Myeloid Leukaemia: PHA Responsiveness and Serum Inhibitory Factors |
title_full | Immunological Studies in Acute Myeloid Leukaemia: PHA Responsiveness and Serum Inhibitory Factors |
title_fullStr | Immunological Studies in Acute Myeloid Leukaemia: PHA Responsiveness and Serum Inhibitory Factors |
title_full_unstemmed | Immunological Studies in Acute Myeloid Leukaemia: PHA Responsiveness and Serum Inhibitory Factors |
title_short | Immunological Studies in Acute Myeloid Leukaemia: PHA Responsiveness and Serum Inhibitory Factors |
title_sort | immunological studies in acute myeloid leukaemia: pha responsiveness and serum inhibitory factors |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2008775/ https://www.ncbi.nlm.nih.gov/pubmed/4511988 |
work_keys_str_mv | AT walkerjs immunologicalstudiesinacutemyeloidleukaemiapharesponsivenessandseruminhibitoryfactors AT davisd immunologicalstudiesinacutemyeloidleukaemiapharesponsivenessandseruminhibitoryfactors AT daviesp immunologicalstudiesinacutemyeloidleukaemiapharesponsivenessandseruminhibitoryfactors AT freemancb immunologicalstudiesinacutemyeloidleukaemiapharesponsivenessandseruminhibitoryfactors AT harrisr immunologicalstudiesinacutemyeloidleukaemiapharesponsivenessandseruminhibitoryfactors |